Vertex Pharmaceuticals’ Alyftrek Receives the CHMP’s Positive Opinion for the Treatment of Cystic Fibrosis

S

R

Shots:   

• The CHMP has recommended Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) to treat patients (≥6yrs.) with cystic fibrosis (CF), having at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Alyftrek is approved in the US and UK and is under review in Canada, Switzerland, Australia, and New Zealand
• Vanzacaftor & tezacaftor help increase CFTR protein at the cell surface, while deutivacaftor enhances its function by boosting channel open probability to improve salt and water flow
• In trials, Alyftrek matched Kaftrio (ivacaftor/tezacaftor/elexacaftor) on ppFEV1 and outperformed it in reducing sweat chloride

Ref: Vertex  | Image: Vertex 

Related News:- Vertex Receives the US FDA Approval for Journavx (Suzetrigine) to Treat Acute Pain

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com